BTK Degrading PROTAC via E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BTK inhibitors are not potent enough and lack alternative strategies for degrading BTK, which is crucial for treating autoimmune and inflammatory diseases as well as cancer.
Innovation Solution
Development of novel bifunctional compounds that conjugate BTK inhibitor moieties with E3 ligase ligands to recruit targeted proteins to E3 ubiquitin ligase for degradation, utilizing the ubiquitin-proteasome system for specific protein knockdown.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional BTK inhibitors are used, then BTK activity is inhibited, but the inhibition potency is insufficient and alternative degradation strategies are lacking
Solution Approach 1:
The BTK inhibitor molecule is segmented into two functional moieties: a BTK-binding moiety that recognizes and binds to BTK, and an E3 ligase-binding moiety that recruits E3 ubiquitin ligase. These moieties are connected by a linker to form a bifunctional PROTAC compound, enabling simultaneous engagement of both BTK and E3 ligase to induce targeted protein degradation
Solution Approach 2:
The bifunctional compound acts as an intermediary molecule that bridges BTK and E3 ubiquitin ligase. By containing both BTK-binding and E3 ligase-binding moieties, it facilitates the formation of a ternary complex that brings these two proteins into proximity, enabling ubiquitination and subsequent degradation of BTK through the proteasome system
2Adaptability or versatility
If bifunctional PROTAC compounds are developed, then alternative BTK degradation strategy is achieved, but the molecular complexity increases
Solution Approach 1:
The bifunctional compound is designed with multi-functionality: it simultaneously serves as a BTK binder, an E3 ligase recruiter, and a molecular scaffold that orchestrates the degradation process. This universal design allows a single molecule to perform multiple functions that would otherwise require separate therapeutic agents
Solution Approach 2:
The PROTAC compound is constructed as a composite molecular structure combining chemically distinct functional moieties (BTK-binding group, linker, E3 ligase-binding group) into a single integrated molecule. This composite approach allows optimization of each moiety's function while maintaining overall molecular stability and activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit BTK activity through degradation, offering a potent approach for treating autoimmune and inflammatory diseases, as well as cancer by precisely regulating BTK levels.
Implementation Method 1
Ubiquitin, which is highly conserved in eukaryotic cells, is a modifier molecule, composed of 76 amino acids, that covalently binds to and labels target substrates via a cascade of enzymatic reactions involving E1, E2, and E3 enzymes.
Implementation Method 2
Subsequently, the modified substrate is recognized by the 26S proteasome complex for ubiquitination-mediated degradation.
Data Source
AI summary
Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.